Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - January 2011
Publisher Name » GlobalData
Published Date » 2011-01-25
No. Of Pages » 68
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - January 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2010. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Content:
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, December 2010
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, December 2010
2.2.1 Novartis Receives Alcon's Board Approval For The Acquisition Of Remaining 23% Stake
2.2.2 Thermo Fisher Scientific To Acquire Dionex
2.2.3 Cephalon Enters Into Licensing Agreement With Mesoblast
2.2.4 Hypermarcas To Acquire Mantecorp Industria Quimica e Farmaceutica
2.2.5 CVS Caremark To Acquire Universal American
2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, December 2010
3 Pharmaceuticals and Healthcare, Deals Summary, by Type
3.1 Pharmaceuticals and Healthcare, Global, M&A, December 2010
3.1.1 Top M&A Deals in December 2010
3.1.2 Pharmaceuticals and Healthcare, Global, M&A Deals by Therapy Area, July 2010 - December 2010
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, December 2010
3.2.1 Top Equity Offering Deals in December 2010
3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, July 2010 - December 2010
3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, December 2010
3.3.1 Top Debt Offering Deals in December 2010
3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, July 2010 - December 2010
3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, December 2010
3.4.1 Top PE/VC Deals in December 2010
3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, December 2010
3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, December 2010
3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, July 2010 - December 2010
3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2010 - December 2010
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, December 2010
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, December 2010
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, July 2010 - December 2010
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), December 2010
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, December 2010
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2010 - December 2010
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), July 2010 - December 2010
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2010 - December 2010
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, December 2010
5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, December 2010
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2010
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, December 2010
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, December 2010
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payments, December 2010
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal values (US$ m), July 2010 - December 2010
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), July 2010 - December 2010
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), July 2010 - December 2010
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), July 2010 - December 2010
6 Deal Summary by Therapy Area
6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, December 2010
6.1.1 Oncology - Deals of the Month
6.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, December 2010
6.2.1 Central Nervous System - Deals of the Month
6.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, December 2010
6.3.1 Infectious Diseases - Deals of the Month
6.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, December 2010
6.4.1 Immunology - Deals of the Month
6.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders Deals, December 2010
6.5.1 Metabolic Disorders - Deals of the Month
6.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, December 2010
6.6.1 Cardiovascular - Deals of the Month
6.7 Pharmaceuticals and Healthcare, Global, Dermatology Deals, December 2010
6.7.1 Dermatology - Deals of the Month
7 Deal Summary by Geography
7.1 Pharmaceuticals and Healthcare, North America, Regional Deals, December 2010
7.1.1 North America - Deals of the Month
7.2 Pharmaceuticals and Healthcare, Europe, Regional Deals, December 2010
7.2.1 Europe - Deals of the Month
7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, December 2010
7.3.1 Asia-Pacific - Deals of the Month
7.4 Pharmaceuticals and Healthcare, Rest of the World Deals, December 2010
7.4.1 Rest of the World - Deals of the Month
8 Pharmaceuticals and Healthcare, Top Advisors
8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, M&A, July 2010 - December 2010
8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, July 2010 - December 2010
9 Further Information
9.1 Methodology
9.2 About GlobalData
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer
Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 9
Table 2: Pharmaceuticals and Healthcare, Global, Top Deals, December 2010 10
Table 3: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), December 2010 12
Table 4: Pharmaceuticals and Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, December 2010 14
Table 6: Pharmaceuticals and Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2010 December 2010 15
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 16
Table 8: Pharmaceuticals and Healthcare, Global, Top Equity Offering Deals, December 2010 17
Table 9: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 18
Table 10: Pharmaceuticals and Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 19
Table 11: Pharmaceuticals and Healthcare, Global, Top Debt Offering Deals, December 2010 20
Table 12: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), July 2010 December 2010 21
Table 13: Pharmaceuticals and Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 22
Table 14: Pharmaceuticals and Healthcare, Global, Top PE/VC Deals, December 2010 23
Table 15: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, July 2010 December 2010 24
Table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), December 2010 25
Table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2010 December 2010 26
Table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2010 December 2010 27
Table 19: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2010 December 2010 28
Table 20: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 29
Table 21: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 30
Table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), December 2010 31
Table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 32
Table 24: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2010 December 2010 33
Table 25: Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), July 2010 December 2010 34
Table 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 35
Table 27: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 36
Table 28: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Deal Value, December 2010 37
Table 29: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payment, December 2010 37
Table 30: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payments, December 2010 38
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), July 2010 December 2010 39
Table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), December 2010 40
Table 33: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2010 December 2010 41
Table 34: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2010 42
Table 35: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 44
Table 36: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 46
Table 37: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 48
Table 38: Pharmaceuticals and Healthcare, Global, Immunology Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 50
Table 39: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 52
Table 40: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 54
Table 41: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 55
Table 42: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 58
Table 43: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 60
Table 44: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 62
Table 45: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 63
Table 46: Pharmaceuticals and Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), July 2010 December 2010 65
Table 47: Pharmaceutical and Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2010 December 2010 66
Figure 1:Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), July 2010 December 2010 8
Figure 2:Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),December 2010 12
Figure 3:Pharmaceuticals and Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), July 2010 December 2010 13
Figure 4:Pharmaceuticals and Healthcare, Global, M&A by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2010 December 2010 14
Figure 5:Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), July 2010 December 2010 16
Figure 6:Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 17
Figure 7:Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), July 2010 December 2010 19
Figure 8:Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 21
Figure 9:Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), July 2010 December 2010 22
Figure 10: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2010 December 2010 24
Figure 11:Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), December 2010 25
Figure 12:Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2010 December 2010 26
Figure 13:Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2010 December 2010 28
Figure 14:Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 29
Figure 15:Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), July 2010 December 2010 30
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 32
Figure 17:Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2010 December 2010 33
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2010 December 2010 34
Figure 19: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), July 2010 December 2010 35
Figure 20: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), July 2010 December 2010 39
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 40
Figure 23:Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), July 2010 December 2010 41
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), December 2010 42
Figure 25:Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), July 2010 December 2010 43
Figure 26:Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), July 2010 December 2010 45
Figure 27:Pharmaceuticals and Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), July 2010 December 2010 47
Figure 28:Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), July 2010 December 2010 49
Figure 29:Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 51
Figure 30:Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 53
Figure 31:Pharmaceuticals and Healthcare, Global, Dermatology, Number of Deals and Deal Values (US$ m), July 2010 December 2010 55
Figure 32:Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), July 2010 December 2010 57
Figure 33:Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), July 2010 December 2010 59
Figure 34:Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), July 2010 December 2010 61
Figure 35:Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), July 2010 December 2010 63
Figure 36:Pharmaceuticals and Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), July 2010 December 2010 65
Figure 37:Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2010 December 2010 66
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, December 2010
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, December 2010
2.2.1 Novartis Receives Alcon's Board Approval For The Acquisition Of Remaining 23% Stake
2.2.2 Thermo Fisher Scientific To Acquire Dionex
2.2.3 Cephalon Enters Into Licensing Agreement With Mesoblast
2.2.4 Hypermarcas To Acquire Mantecorp Industria Quimica e Farmaceutica
2.2.5 CVS Caremark To Acquire Universal American
2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, December 2010
3 Pharmaceuticals and Healthcare, Deals Summary, by Type
3.1 Pharmaceuticals and Healthcare, Global, M&A, December 2010
3.1.1 Top M&A Deals in December 2010
3.1.2 Pharmaceuticals and Healthcare, Global, M&A Deals by Therapy Area, July 2010 - December 2010
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, December 2010
3.2.1 Top Equity Offering Deals in December 2010
3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, July 2010 - December 2010
3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, December 2010
3.3.1 Top Debt Offering Deals in December 2010
3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, July 2010 - December 2010
3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, December 2010
3.4.1 Top PE/VC Deals in December 2010
3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, December 2010
3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, December 2010
3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, July 2010 - December 2010
3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2010 - December 2010
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, December 2010
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, December 2010
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, July 2010 - December 2010
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), December 2010
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, December 2010
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2010 - December 2010
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), July 2010 - December 2010
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2010 - December 2010
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, December 2010
5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, December 2010
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2010
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, December 2010
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, December 2010
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payments, December 2010
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal values (US$ m), July 2010 - December 2010
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), July 2010 - December 2010
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), July 2010 - December 2010
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), July 2010 - December 2010
6 Deal Summary by Therapy Area
6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, December 2010
6.1.1 Oncology - Deals of the Month
6.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, December 2010
6.2.1 Central Nervous System - Deals of the Month
6.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, December 2010
6.3.1 Infectious Diseases - Deals of the Month
6.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, December 2010
6.4.1 Immunology - Deals of the Month
6.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders Deals, December 2010
6.5.1 Metabolic Disorders - Deals of the Month
6.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, December 2010
6.6.1 Cardiovascular - Deals of the Month
6.7 Pharmaceuticals and Healthcare, Global, Dermatology Deals, December 2010
6.7.1 Dermatology - Deals of the Month
7 Deal Summary by Geography
7.1 Pharmaceuticals and Healthcare, North America, Regional Deals, December 2010
7.1.1 North America - Deals of the Month
7.2 Pharmaceuticals and Healthcare, Europe, Regional Deals, December 2010
7.2.1 Europe - Deals of the Month
7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, December 2010
7.3.1 Asia-Pacific - Deals of the Month
7.4 Pharmaceuticals and Healthcare, Rest of the World Deals, December 2010
7.4.1 Rest of the World - Deals of the Month
8 Pharmaceuticals and Healthcare, Top Advisors
8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, M&A, July 2010 - December 2010
8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, July 2010 - December 2010
9 Further Information
9.1 Methodology
9.2 About GlobalData
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer
List of Tables
Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 9
Table 2: Pharmaceuticals and Healthcare, Global, Top Deals, December 2010 10
Table 3: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), December 2010 12
Table 4: Pharmaceuticals and Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, December 2010 14
Table 6: Pharmaceuticals and Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2010 December 2010 15
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 16
Table 8: Pharmaceuticals and Healthcare, Global, Top Equity Offering Deals, December 2010 17
Table 9: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 18
Table 10: Pharmaceuticals and Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 19
Table 11: Pharmaceuticals and Healthcare, Global, Top Debt Offering Deals, December 2010 20
Table 12: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), July 2010 December 2010 21
Table 13: Pharmaceuticals and Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 22
Table 14: Pharmaceuticals and Healthcare, Global, Top PE/VC Deals, December 2010 23
Table 15: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, July 2010 December 2010 24
Table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), December 2010 25
Table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2010 December 2010 26
Table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2010 December 2010 27
Table 19: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2010 December 2010 28
Table 20: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 29
Table 21: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 30
Table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), December 2010 31
Table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 32
Table 24: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2010 December 2010 33
Table 25: Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), July 2010 December 2010 34
Table 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 35
Table 27: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 36
Table 28: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Deal Value, December 2010 37
Table 29: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payment, December 2010 37
Table 30: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payments, December 2010 38
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), July 2010 December 2010 39
Table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), December 2010 40
Table 33: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2010 December 2010 41
Table 34: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2010 42
Table 35: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 44
Table 36: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 46
Table 37: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 48
Table 38: Pharmaceuticals and Healthcare, Global, Immunology Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 50
Table 39: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 52
Table 40: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 54
Table 41: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 55
Table 42: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 58
Table 43: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 60
Table 44: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 62
Table 45: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 63
Table 46: Pharmaceuticals and Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), July 2010 December 2010 65
Table 47: Pharmaceutical and Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2010 December 2010 66
List of Figures
Figure 1:Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), July 2010 December 2010 8
Figure 2:Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),December 2010 12
Figure 3:Pharmaceuticals and Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), July 2010 December 2010 13
Figure 4:Pharmaceuticals and Healthcare, Global, M&A by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2010 December 2010 14
Figure 5:Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), July 2010 December 2010 16
Figure 6:Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 17
Figure 7:Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), July 2010 December 2010 19
Figure 8:Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 21
Figure 9:Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), July 2010 December 2010 22
Figure 10: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2010 December 2010 24
Figure 11:Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), December 2010 25
Figure 12:Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2010 December 2010 26
Figure 13:Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2010 December 2010 28
Figure 14:Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2010 December 2010 29
Figure 15:Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), July 2010 December 2010 30
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 32
Figure 17:Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2010 December 2010 33
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2010 December 2010 34
Figure 19: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), July 2010 December 2010 35
Figure 20: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), July 2010 December 2010 39
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2010 December 2010 40
Figure 23:Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), July 2010 December 2010 41
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), December 2010 42
Figure 25:Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), July 2010 December 2010 43
Figure 26:Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), July 2010 December 2010 45
Figure 27:Pharmaceuticals and Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), July 2010 December 2010 47
Figure 28:Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), July 2010 December 2010 49
Figure 29:Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 51
Figure 30:Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 December 2010 53
Figure 31:Pharmaceuticals and Healthcare, Global, Dermatology, Number of Deals and Deal Values (US$ m), July 2010 December 2010 55
Figure 32:Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), July 2010 December 2010 57
Figure 33:Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), July 2010 December 2010 59
Figure 34:Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), July 2010 December 2010 61
Figure 35:Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), July 2010 December 2010 63
Figure 36:Pharmaceuticals and Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), July 2010 December 2010 65
Figure 37:Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2010 December 2010 66
Upcoming Reports:
|
Bio-Based Organic Acids Market - Global Industry Analysis, Size, Share, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Since the last decade, the demand for bio-based organic acids is growing at a steady pace owing to the impact of conventional organic acids on the environment. In order to cater to this growing demand, more and more organic acid is being produced from renewable sources such as feedstock.
The market for organic acid synthesized from renewable raw material is also driven by the stringent regulations imposed by regulatory bodies of various nations on conventional organic acid producers. Bio-based alternatives for organic acid are eco-friendly and are frugal compared...
|
|
SNP Genotyping And Analysis Markets And The Future Of Snps In Personalized Medicine
By - Transparency Market Research
SNP (single nucleotide polymorphism) analysis is the most common type of genetic variation between human beings and can be ideal for identifying the correlation between genotype and behavior of living organisms. Due to this reason, SNP analysis represents one of many pathways to personalized medicine. SNP analysis is used in different fields for specialized purposes; however, diagnostics and pharmacogenomics are the most promising applications of single nucleotide polymorphism.
The SNP genotyping and analysis market is forecasted to witness double digit growth in...
|
|
Antibody Drugs Market, Global Forecast, Market Share, Size, Growth And Industry Analysis, 2012 - 2018
By - Transparency Market Research
Antibody drugs make use of the body’s own immune system to locate and eliminate cells which are responsible for the target disease. Antibody drugs have been successful in attracting the attention of researchers worldwide owing to their characteristic features such as fewer side effects and high efficacy in curing certain diseases which were previously untreatable.
Large scale research development is being conducted in the field of antibody drugs for the past two decades. By 2009, approximately 30 new antibody drugs were launched in the market. With an intention of...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Share this report
Latest Reports
- The Future of the Haircare Market in Egypt to 2017
- The Future of the Haircare Market in Denmark to 2017
- Overview of international chemical market
- Russian market of microcredits and lending to SME in Russia
- Overview of furniture market
- The Future of the Haircare Market in Czech Republic to 2017
- LTE Strategy 2013 - 2018
- Natural And Synthetic (Ethoxyquin, BHA, BHT) Animal Feed Antioxidants Market For Swine, Poultry, Cattle And Aquaculture - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
- Seed Treatment Market (Insecticides, Fungicides, Other Chemical And Nonchemical Treatment) For Corn, Soybean, Wheat, Canola, Cotton And Others - Global Industry Analysis, Size, Share, Growth And Forecast, 2012 - 2018
- Future of the Spanish Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
